Compare Sana Biotechnology Inc (SANA) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Virgin Galactic Holdings, Inc. — how do they compare? Sana Biotechnology Inc trades at $2.85 (market cap $836.71M), while Virgin Galactic Holdings, Inc. trades at $2.87 (market cap $445.69M). The key difference: Sana Biotechnology Inc is the larger of the two by market cap, and Virgin Galactic Holdings, Inc. is more actively traded (5,128,850 versus 4,507,444). Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Virgin Galactic Holdings, Inc. for 69 Days on average.
| SANA | SPCE | |
|---|---|---|
Market Cap | $836.71M | $445.69M |
Volume | 4,507,444 | 5,128,850 |
Sector | Health | Industrials |
52-Week High | $5.92 | $7.52 |
52-Week Low | $2.68 | $2.17 |
Typical Hold Time | 23 Days | 69 Days |
Enterprise Value | $749.96M | $409.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
SPCE trades at $2.875, down 4.49% on the day, reflecting ongoing volatility amid negative profitability and cash burn. The company continues to post significant losses, with a net income margin of -23,867.44% in 2025, though recent quarters have shown smaller-than-expected EPS losses. Technical indicators are bearish, with moving averages signaling selling pressure, while RSI levels suggest potential oversold conditions. Recent news highlights a delay in commercial Delta flights to 2027 but strong ticket demand and a legal settlement resolution.
The outlook remains high-risk due to persistent cash outflows and delayed revenue growth, yet long-term potential in space tourism offers speculative upside. Investment hinges on successful execution of the 2027 cash flow target and commercial flight timeline, but shareholder dilution and high short interest pose substantial risks. Analyst consensus is mixed, with 29% buy ratings reflecting cautious optimism amid fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
